Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 6.74Vaishali Pharma Ltd, operating within the Healthcare Services sector, demonstrates a mixed financial performance. The company exhibits strong solvency and growth, driven by effective management of debt and significant increases in revenue and net income. Profitability is also a notable strength, supported by healthy gross profit and operating margins. However, the company faces challenges in liquidity, particularly with low cash and operating cash flow ratios. Efficiency metrics are varied, with strong asset and inventory turnover balanced by slow receivables turnover. Overall, the company shows potential for continued growth, but needs to address its liquidity and efficiency in certain areas to ensure long-term financial stability.
Health Score : 6.74Vaishali Pharma Ltd, operating within the Healthcare Services sector, demonstrates a mixed financial performance. The company exhibits strong solvency and growth, driven by effective management of debt and significant increases in revenue and net income. Profitability is also a notable strength, supported by healthy gross profit and operating margins. However, the company faces challenges in liquidity, particularly with low cash and operating cash flow ratios. Efficiency metrics are varied, with strong asset and inventory turnover balanced by slow receivables turnover. Overall, the company shows potential for continued growth, but needs to address its liquidity and efficiency in certain areas to ensure long-term financial stability.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
25.90
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
25.09
P/B RATIO
1.52
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
0.85
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
12.21
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹8.03 as on Sep 1, 2026.
Growth Score : 8.80The company demonstrates strong growth in several key areas, including revenue, EPS, asset, and net income. However, the negative operating profit growth rate raises concerns about the sustainability of this growth. The weighted average calculation, emphasizing recent performance, suggests that while the company is expanding, operational efficiency and profitability need attention to ensure balanced and sustainable growth.
Revenue Growth RateExcellent
Operating Profit Growth RatePoorEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellentRevenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Par Drugs & Chemicals Ltd | 7.40 | 13.20 | Neutral | 17.00 | 10.65 | 13.00 |
| 2 | Vaishali Pharma Ltd | 6.74 | 25.09 | Neutral | 4.00 | 0.31 | 4.00 |
| 3 | Mono Pharmacare Ltd | 6.16 | 42.75 | Neutral | 4.00 | 0.20 | N/A |
| 4 | JFL Life Sciences Ltd | 6.07 | 10.88 | Neutral | 12.00 | 1.94 | 6.00 |
| 5 | Walpar Nutritions Ltd | 5.29 | 9.89 | Neutral | 6.66 | 2.09 | 3.00 |
| 6 | Quest Laboratories Ltd | 5.27 | 9.34 | Neutral | 18.00 | 9.16 | 15.00 |
| 7 | Sotac Pharmaceuticals Ltd | 5.27 | 17.25 | Neutral | 18.00 | 4.45 | 6.00 |
| 8 | Zenith Drugs Ltd | 4.63 | 7.41 | Neutral | 17.00 | 2.30 | 10.00 |
| 9 | Mangalam Drugs and Organics Ltd | 4.50 | -1.06 | Neutral | -15.00 | -27.68 | -44.00 |
| 10 | Lasa Supergenerics Ltd | 4.39 | -2.61 | Highly Undervalued | -7.00 | -6.80 | -34.00 |
| 11 | Krebs Biochemicals & Industries Ltd | 4.16 | -4.36 | Highly Undervalued | -4.00 | -7.85 | -4.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Vaishali Pharma Ltd is an Indian pharmaceutical company primarily involved in manufacturing, trading, and exporting various pharmaceutical products. Its portfolio encompasses Active Pharmaceutical Ingredients (APIs), finished formulations, herbal products, and veterinary medicines, catering to both domestic and international markets.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Vaishali Pharma Ltd's P/E ratio (TTM) is 25.90, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Vaishali Pharma Ltd's P/B ratio is 1.52, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Vaishali Pharma Ltd's P/S ratio is 0.85, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Vaishali Pharma Ltd's PEG ratio is N/A.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Vaishali Pharma Ltd's EV/EBITDA ratio is 12.21.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Vaishali Pharma Ltd's ROE is 5.80%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Vaishali Pharma Ltd's ROA is 3.25%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Vaishali Pharma Ltd's ROCE is 9.33%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Vaishali Pharma Ltd's operating margin is 3.67%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Vaishali Pharma Ltd's net margin is 3.67%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Vaishali Pharma Ltd's current ratio is 2.42.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Vaishali Pharma Ltd's debt-to-equity ratio is 0.09.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Vaishali Pharma Ltd's interest coverage ratio is 3.50.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Vaishali Pharma Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Vaishali Pharma Ltd's EPS is 0.31.
(Source line: "Ratios as of 26 Sept 2026, based on last traded price of ₹8.03. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2008
Headquarters: Mumbai, Maharashtra
Core Offerings: APIs, Pharmaceutical Formulations, Herbal & Nutraceutical Products, Veterinary Products
Stock Listing: NSE (VAISHALI), BSE ({bse})
Promoter: Atul Kakubhai Gandhi / Gandhi Family
Vaishali Pharma Ltd was incorporated in 2008, initially focusing on the trading and export of pharmaceutical products. Over the years, it expanded its operations into manufacturing and diversified its product portfolio to include Active Pharmaceutical Ingredients (APIs), finished formulations, herbal products, and veterinary medicines, serving a growing domestic and international clientele.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Active Pharmaceutical Ingredients (APIs) | N/A | Operating Profit |
| Pharmaceutical Formulations | N/A | Operating Profit |
| Herbal, Nutraceutical & Veterinary Products | N/A | Operating Profit |
Active Pharmaceutical Ingredients (APIs): Engaged in the manufacturing, trading, and export of various APIs across different therapeutic segments.
Finished Formulations: Offers a wide range of pharmaceutical formulations including tablets, capsules, liquids, injections, and ointments.
Herbal & Nutraceuticals: Deals in herbal products, dietary supplements, and nutraceuticals for health and wellness.
Veterinary Products: Provides pharmaceutical solutions specifically for animal health.
Mr. Atul Kakubhai Gandhi serves as the Chairman & Managing Director. He is a key promoter and plays a pivotal role in the company's strategic planning and business expansion.
No major subsidiaries reported.
Bonus issue (1:1 in May 2022); Stock split (10:1 in Feb 2023).
The Vaishali Pharma Ltd share price today is ₹8.03 on NSE (VAISHALI), as of 26 Sept 2026.
As of 26 Sept 2026, Vaishali Pharma Ltd share price is ₹8.03, with previous close ₹8.03. Today's range is ₹8.03 to ₹8.03. The 52-week range is ₹4.75 to ₹9.80.
As of today, Vaishali Pharma Ltd's market cap is ₹92.51 crore (Small Cap).
Vaishali Pharma Ltd's current P/E ratio is 25.90, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 33.50.
Vaishali Pharma Ltd's current P/B ratio is 1.52.
Vaishali Pharma Ltd's current dividend yield is N/A. Last dividend of ₹0.10 per share was declared on 25-Aug-2023.
Vaishali Pharma Ltd's EPS (TTM) is ₹0.31.
Vaishali Pharma Ltd is an Indian pharmaceutical company primarily involved in manufacturing, trading, and exporting various pharmaceutical products. Its portfolio encompasses Active Pharmaceutical Ingredients (APIs), finished formulations, herbal products, and veterinary medicines, catering to both domestic and international markets.
Vaishali Pharma Ltd is promoted by Atul Kakubhai Gandhi / Gandhi Family, holding 31.61% as of 26 Sept 2026.
Vaishali Pharma Ltd is listed on NSE (VAISHALI) and BSE ({bse}). Its next quarterly results are expected on May 2024 (for Q4 FY24).
